NCT03142529 is a Phase 1, PHASE2 clinical trial of colon lotion in Chronic Kidney Failure, sponsored by Pang Peng.

Who is sponsoring NCT03142529?

NCT03142529 is sponsored by Pang Peng.

What drugs are being tested in NCT03142529?

Interventions in NCT03142529: colon lotion.

What condition does NCT03142529 study?

NCT03142529 studies Chronic Kidney Failure, End-Stage Kidney Disease.

Is NCT03142529 still recruiting?

NCT03142529 is currently status unknown. Last updated 30 May 2018.

Last reviewed 2018-05-30 · How we verify

NCT03142529

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Traditional Chinese Medicine (TCM) Colon Dialysis Treats Non-dialysis End-Stage Kidney Disease

Status unknown Phase 1, PHASE2 Last updated 30 May 2018

What this trial tests

Phase 1, PHASE2 trial testing colon lotion in Chronic Kidney Failure in 20 participants. Status unknown.

Timeline

15 May 2017

Primary endpoint
15 August 2018

15 October 2018

Quick facts

Lead sponsor	Pang Peng
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	15 May 2017
Primary completion	15 August 2018
Estimated completion	15 October 2018
Sites	1 location across China

Drugs / interventions tested

colon lotion — full drug profile →

Conditions studied

Chronic Kidney Failure — all drugs for Chronic Kidney Failure →
End-Stage Kidney Disease — all drugs for End-Stage Kidney Disease →

Sponsor

Pang Peng — full company profile →

Who can join

Adults 18 to 80, any sex, with Chronic Kidney Failure or End-Stage Kidney Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates the clinical efficacy and study the therapeutic mechanism of a kind of traditional Chinese medicine colonic dialysis on Chronic kidney disease (CKD) 5 without blood dialysis therapy in adults. Half of participants will receive conventional integrated therapy on chronic renal failure (CRF), while the other half will receive integrated therapy on CRF and traditional Chinese medicine colonic dialysis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Chronic Kidney Failure

Currently open trials in the same condition.

NCT07348237 — A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006) · Phase 1 · recruiting
NCT06981585 — Physical Impairments in Children With Chronic Renal Failure · recruiting
NCT06660160 — Group Exercise Program Supported By Audiovisual Media During Hemodialysis · NA · active not recruiting
NCT05562869 — Belatacept as a Replacement for CNIs 3 to 12 Months Post-transplantation in Patients With Early Graft Dysfunction · Phase 3 · recruiting
NCT05445219 — Identifying Therapeutic Hemodialysis Targets Through Cerebrovascular Reactivity; RESPIRACT 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03142529 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pang Peng
Last refreshed: 30 May 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03142529.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing